Sun Pharmaceutical Industries Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1771.65 -3.55 (-0.20%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1759.4
Today’s High
1791.3
52 Week Low
1180.1
52 Week High
1960.2
1780.00 +2.75 (0.15%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1758.05
Today’s High
1791.45
52 Week Low
1184.5
52 Week High
1960.35
Key Metrics
- Market Cap (In Cr) 426381.4
- Beta 0.79
- Div. Yield (%) 0.76
- P/B 6.7
- TTM P/E 41.78
- Peg Ratio 0.79
- Sector P/E 31.15
- D/E 0.04
- Open Price 1778.25
- Prev Close 1775.2
Sun Pharmaceutical Industries Analysis
Price Analysis
-
1 Week-0.97%
-
3 Months0.62%
-
6 Month15.33%
-
YTD41.11%
-
1 Year49.6%
Risk Meter
- 18% Low risk
- 18% Moderate risk
- 18% Balanced Risk
- 18% High risk
- 18% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 10
- 10
- 8
- 8
- Buy
- 12
- 12
- 15
- 13
- Hold
- 8
- 8
- 8
- 9
- Sell
- 3
- 3
- 1
- 1
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 33
- 33
- 32
- 31
Sun Pharmaceutical Industries News
Sunrest Lifescience, MT Educare & others hit 52 week low today ;Check the full list here?
4 min read . 05 Nov 2024Tilaknagar Industries, Aditya Birla Sun Life AMC & others hit 52 week high today ; Do you own any?
3 min read . 05 Nov 2024Adani's net worth grows by ₹10 lakh crore in 5 years: Check India's top gainers
2 min read . 30 Oct 2024Sun Pharmaceutical Industries Q2 Results Live: Profit Rises by 27.98% YoY
1 min read . 29 Oct 2024Sun Pharmaceutical Industries Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 48496.85
- Selling/ General/ Admin Expenses Total
- 9429.06
- Depreciation/ Amortization
- 2556.64
- Other Operating Expenses Total
- 15418.18
- Total Operating Expense
- 38560.81
- Operating Income
- 9936.04
- Net Income Before Taxes
- 11087.89
- Net Income
- 9576.38
- Diluted Normalized EPS
- 41.69
- Period
- 2024
- Total Assets
- 85462.88
- Total Liabilities
- 21796.13
- Total Equity
- 63666.75
- Tangible Book Valueper Share Common Eq
- 193.39
- Period
- 2024
- Cashfrom Operating Activities
- 12136.27
- Cashfrom Investing Activities
- -690.2
- Cashfrom Financing Activities
- -6710.16
- Net Changein Cash
- 4661.92
- Period
- 2023
- Total Revenue
- 43885.68
- Selling/ General/ Admin Expenses Total
- 19394.87
- Depreciation/ Amortization
- 2529.43
- Other Operating Expenses Total
- 738.24
- Total Operating Expense
- 34793.33
- Operating Income
- 9092.35
- Net Income Before Taxes
- 9408.43
- Net Income
- 8473.58
- Diluted Normalized EPS
- 36.01
- Period
- 2023
- Total Assets
- 80743.59
- Total Liabilities
- 24748.21
- Total Equity
- 55995.38
- Tangible Book Valueper Share Common Eq
- 158.19
- Period
- 2023
- Cashfrom Operating Activities
- 5526.02
- Cashfrom Investing Activities
- -7943.68
- Cashfrom Financing Activities
- 2376.07
- Net Changein Cash
- 115.48
- Period
- 2022
- Total Revenue
- 38654.49
- Selling/ General/ Admin Expenses Total
- 15945.42
- Depreciation/ Amortization
- 2143.74
- Other Operating Expenses Total
- 709.74
- Total Operating Expense
- 35076.82
- Operating Income
- 3577.67
- Net Income Before Taxes
- 4481.32
- Net Income
- 3272.73
- Diluted Normalized EPS
- 28.03
- Period
- 2022
- Total Assets
- 69807.77
- Total Liabilities
- 21796.55
- Total Equity
- 48011.22
- Tangible Book Valueper Share Common Eq
- 146.82
- Period
- 2022
- Cashfrom Operating Activities
- 9025.99
- Cashfrom Investing Activities
- -5724.74
- Cashfrom Financing Activities
- -5193.46
- Net Changein Cash
- -1764.78
- Period
- 2021
- Total Revenue
- 33498.14
- Selling/ General/ Admin Expenses Total
- 14344.76
- Depreciation/ Amortization
- 2079.95
- Other Operating Expenses Total
- 734.39
- Total Operating Expense
- 31351.52
- Operating Income
- 2146.62
- Net Income Before Taxes
- 2799.37
- Net Income
- 2903.82
- Diluted Normalized EPS
- 26.71
- Period
- 2021
- Total Assets
- 67666.73
- Total Liabilities
- 21203.95
- Total Equity
- 46462.78
- Tangible Book Valueper Share Common Eq
- 143.85
- Period
- 2021
- Cashfrom Operating Activities
- 6170.37
- Cashfrom Investing Activities
- 536.22
- Cashfrom Financing Activities
- -5980.48
- Net Changein Cash
- 596.42
- Period
- 2020
- Total Revenue
- 32837.5
- Selling/ General/ Admin Expenses Total
- 14593.92
- Depreciation/ Amortization
- 2052.78
- Other Operating Expenses Total
- 771.72
- Total Operating Expense
- 28129.12
- Operating Income
- 4708.38
- Net Income Before Taxes
- 5009.59
- Net Income
- 3764.93
- Diluted Normalized EPS
- 16.54
- Period
- 2020
- Total Assets
- 68252.46
- Total Liabilities
- 22988.01
- Total Equity
- 45264.45
- Tangible Book Valueper Share Common Eq
- 135.14
- Period
- 2020
- Cashfrom Operating Activities
- 6554.77
- Cashfrom Investing Activities
- -2588.84
- Cashfrom Financing Activities
- -5715.14
- Net Changein Cash
- -1385.69
- Period
- 2019
- Total Revenue
- 29065.91
- Selling/ General/ Admin Expenses Total
- 12429.44
- Depreciation/ Amortization
- 1753.25
- Other Operating Expenses Total
- 741.09
- Total Operating Expense
- 25378.21
- Operating Income
- 3687.7
- Net Income Before Taxes
- 3810.2
- Net Income
- 2665.42
- Diluted Normalized EPS
- 15.61
- Period
- 2019
- Total Assets
- 64693.81
- Total Liabilities
- 23284.75
- Total Equity
- 41409.06
- Tangible Book Valueper Share Common Eq
- 121.28
- Period
- 2019
- Cashfrom Operating Activities
- 2241.97
- Cashfrom Investing Activities
- -681.25
- Cashfrom Financing Activities
- -2730.52
- Net Changein Cash
- -844.15
- Period
- 2018
- Total Revenue
- 26489.46
- Selling/ General/ Admin Expenses Total
- 11125.37
- Depreciation/ Amortization
- 1499.84
- Other Operating Expenses Total
- 700.9
- Total Operating Expense
- 23106.4
- Operating Income
- 3383.06
- Net Income Before Taxes
- 3478.98
- Net Income
- 2095.7
- Diluted Normalized EPS
- 12.84
- Period
- 2018
- Total Assets
- 64516.35
- Total Liabilities
- 26202.24
- Total Equity
- 38314.11
- Tangible Book Valueper Share Common Eq
- 114.99
- Period
- 2018
- Cashfrom Operating Activities
- 4026.88
- Cashfrom Investing Activities
- -3370.81
- Cashfrom Financing Activities
- -1539.26
- Net Changein Cash
- -735.91
- Period
- 2024-09-30
- Total Revenue
- 13291.39
- Selling/ General/ Admin Expenses Total
- 2477.7
- Depreciation/ Amortization
- 625.91
- Other Operating Expenses Total
- 4308.62
- Total Operating Expense
- 10106.43
- Operating Income
- 3184.96
- Net Income Before Taxes
- 3597.88
- Net Income
- 3040.16
- Diluted Normalized EPS
- 12.7
- Period
- 2024-09-30
- Total Assets
- 88115.66
- Total Liabilities
- 19000.76
- Total Equity
- 69114.9
- Tangible Book Valueper Share Common Eq
- 212.12
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 6299.47
- Cashfrom Investing Activities
- -2583.96
- Cashfrom Financing Activities
- -5058.05
- Net Changein Cash
- -1273.11
- Period
- 2024-06-30
- Total Revenue
- 12652.75
- Selling/ General/ Admin Expenses Total
- 2454.62
- Depreciation/ Amortization
- 655.13
- Other Operating Expenses Total
- 3864.63
- Total Operating Expense
- 9649.81
- Operating Income
- 3002.94
- Net Income Before Taxes
- 3423.5
- Net Income
- 2835.62
- Diluted Normalized EPS
- 11.8
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 11982.9
- Selling/ General/ Admin Expenses Total
- 2299.34
- Depreciation/ Amortization
- 650.36
- Other Operating Expenses Total
- 4211.62
- Total Operating Expense
- 9643.37
- Operating Income
- 2339.53
- Net Income Before Taxes
- 2815.52
- Net Income
- 2654.58
- Diluted Normalized EPS
- 11.5
- Period
- 2024-03-31
- Total Assets
- 85462.88
- Total Liabilities
- 21796.13
- Total Equity
- 63666.75
- Tangible Book Valueper Share Common Eq
- 193.39
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 12136.27
- Cashfrom Investing Activities
- -690.2
- Cashfrom Financing Activities
- -6710.16
- Net Changein Cash
- 4661.92
- Period
- 2023-12-31
- Total Revenue
- 12380.7
- Selling/ General/ Admin Expenses Total
- 2363.32
- Depreciation/ Amortization
- 622.14
- Other Operating Expenses Total
- 3928.17
- Total Operating Expense
- 9720.38
- Operating Income
- 2660.32
- Net Income Before Taxes
- 3000.35
- Net Income
- 2523.75
- Diluted Normalized EPS
- 10.75
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 12192.41
- Selling/ General/ Admin Expenses Total
- 2364.36
- Depreciation/ Amortization
- 632.82
- Other Operating Expenses Total
- 3827.49
- Total Operating Expense
- 9611.76
- Operating Income
- 2580.65
- Net Income Before Taxes
- 2790.88
- Net Income
- 2375.51
- Diluted Normalized EPS
- 9.9
- Period
- 2023-09-30
- Total Assets
- 79441.16
- Total Liabilities
- 19615.52
- Total Equity
- 59825.64
- Tangible Book Valueper Share Common Eq
- 175.19
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 5719.95
- Cashfrom Investing Activities
- 993.7
- Cashfrom Financing Activities
- -5876.8
- Net Changein Cash
- 779.37
- Period
- 2023-06-30
- Total Revenue
- 11940.84
- Selling/ General/ Admin Expenses Total
- 2402.04
- Depreciation/ Amortization
- 651.32
- Other Operating Expenses Total
- 3450.9
- Total Operating Expense
- 9585.3
- Operating Income
- 2355.54
- Net Income Before Taxes
- 2481.14
- Net Income
- 2022.54
- Diluted Normalized EPS
- 9.49
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 10930.67
- Selling/ General/ Admin Expenses Total
- 2179.55
- Depreciation/ Amortization
- 671.53
- Other Operating Expenses Total
- 3671.6
- Total Operating Expense
- 8944.35
- Operating Income
- 1986.32
- Net Income Before Taxes
- 2239.69
- Net Income
- 1984.47
- Diluted Normalized EPS
- 8.96
- Period
- 2023-03-31
- Total Assets
- 80743.59
- Total Liabilities
- 24748.21
- Total Equity
- 55995.38
- Tangible Book Valueper Share Common Eq
- 158.19
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 5526.02
- Cashfrom Investing Activities
- -7943.68
- Cashfrom Financing Activities
- 2376.07
- Net Changein Cash
- 115.48
- Period
- 2022-12-31
- Total Revenue
- 11240.97
- Selling/ General/ Admin Expenses Total
- 2037.07
- Depreciation/ Amortization
- 659.95
- Other Operating Expenses Total
- 3393.38
- Total Operating Expense
- 8894.07
- Operating Income
- 2346.9
- Net Income Before Taxes
- 2471.47
- Net Income
- 2166.01
- Diluted Normalized EPS
- 9
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Sun Pharmaceutical Industries Technical
Moving Average
SMA
- 5 Day1774.03
- 10 Day1789.84
- 20 Day1823.75
- 50 Day1860.23
- 100 Day1766.38
- 300 Day1645.62
Sun Pharmaceutical Industries Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1771.65
- -3.55
- -0.2
- 1960.2
- 1180.1
- 425078.18
- Divis Laboratories
- 5960
- 63.85
- 1.08
- 6276.2
- 3350.05
- 158219.27
- Cipla
- 1463
- -8.35
- -0.57
- 1702
- 1165.1
- 118121.88
- Torrent Pharmaceuticals
- 3105.4
- 10.6
- 0.34
- 3589.95
- 2025
- 105105.37
- Dr Reddys Laboratories
- 1194.55
- -19.4
- -1.6
- 1420.2
- 1074.35
- 19892.66
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 42.58
- 6.7
- 11.27
- 14.23
- Divis Laboratories
- 97.72
- 11.54
- 18.97
- 26.38
- Cipla
- 27.37
- 4.45
- 13.5
- 12.66
- Torrent Pharmaceuticals
- 65.33
- 15.28
- 20.64
- 13.18
- Dr Reddys Laboratories
- 18.36
- 3.58
- 16.73
- 14.63
Sun Pharmaceutical Industries Shareholding
Shareholding Pattern
*Promoter pledging: 0.43%
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-Oct-24
- Quarterly Results
- 01-Aug-24
- Quarterly Results
- 22-May-24
- Audited Results & Final Dividend
- 31-Jan-24
- Quarterly Results & Interim Dividend
- 01-Nov-23
- Quarterly Results
- 03-Aug-23
- Quarterly Results
- 26-May-23
- Audited Results & Final Dividend
- 31-Jan-23
- Quarterly Results & Interim Dividend
- 01-Nov-22
- Quarterly Results
- 29-Jul-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 05-Aug-24
- 19-Jun-24
- AGM
- 28-Aug-23
- 07-Jul-23
- AGM
- 29-Aug-22
- 03-Aug-22
- AGM
- 31-Aug-21
- 04-Aug-21
- AGM
- 16-Mar-21
- 05-Feb-21
- COM
- 27-Aug-20
- 29-Jul-20
- AGM
- 28-Aug-19
- 26-Jul-19
- AGM
- 04-Jun-19
- 30-Apr-19
- COM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 22-May-24
- 12-Jul-24
- 12-Jul-24
- 5
- 15-Jan-24
- 09-Feb-24
- 09-Feb-24
- 8.5
- 07-Jul-23
- 28-Jul-23
- 28-Jul-23
- 4
- 16-Jan-23
- 08-Feb-23
- 08-Feb-23
- 7.5
- 31-May-22
- 22-Aug-22
- 19-Aug-22
- 3
- 31-Jan-22
- 10-Feb-22
- 09-Feb-22
- 7
- 27-May-21
- -
- 23-Aug-21
- 2
- 29-Jan-21
- 10-Feb-21
- 09-Feb-21
- 5.5
- 27-May-20
- -
- 19-Aug-20
- 1
- 06-Feb-20
- 18-Feb-20
- 17-Feb-20
- 3